Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ COVID-19 Vaccine Scores 79% In Pivotal US Trial – Any Hope For A Fresh Start?

Brain Clot Safety Issue Addressed

Executive Summary

The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.

You may also be interested in...



AstraZeneca Vaccine’s ‘Big Gap’: DSMB Questions Results Released By Firm In Latest Controversy

‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.

Another Fine Mess For AZ As ‘Outdated’ Vaccine Data Queried

A new “unforced error” from AstraZeneca in reporting clinical data is keeping its COVID-19 vaccine in the headlines for the wrong reasons.

Coronavirus Notebook: UK Tests Preventative Treatments As Row Escalates With EU Over Vaccine Supply

The procurement and authorization of vaccines are under scrutiny in the European Parliament this week. In the meantime, another Sputnik V spat is taking wing between Russia and the EU, while France has resumed the use of AstraZeneca’s vaccine, but only in the over-55s.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel